This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fidelity National (FNF) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Fidelity National (FNF) Q4 earnings likely to benefit from higher direct premium, agency premiums as well as escrow, title-related and other fees.
Lemonade (LMND) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Lemonade's (LMND) Q4 results are likely to reflect benefits from the diversification of business mix to higher premium products and multiple policies of customers.
ProAssurance (PRA) to Post Q4 Earnings: What You Need to Know
by Zacks Equity Research
ProAssurance's (PRA) fourth-quarter results are likely to reflect increased net investment income and premiums earned.
BGC Partners (BGCP) Q4 Earnings Match Estimates
by Zacks Equity Research
BGC Partners (BGCP) delivered earnings and revenue surprises of 0% and 5.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 14.29% and 10.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Crescent Capital BDC (CCAP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Crescent Capital BDC (CCAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crescent Capital BDC (CCAP) Q2 Earnings Lag Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of -13.33% and 12.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Crescent Capital BDC (CCAP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Crescent Capital BDC (CCAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crescent Capital BDC (CCAP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Crescent Capital BDC (CCAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crescent Capital BDC (CCAP) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 2.17% and 3.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Crescent Capital BDC (CCAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Crescent Capital BDC, Inc. (CCAP) Rating Upgrade to Buy
by Zacks Equity Research
Crescent Capital BDC, Inc. (CCAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy
5 Stocks to Wade Through Hurdles in Second-Half 2020
by Sreoshi Bera
Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.
Medallion (MFIN) Soars: Stock Moves 9.1% Higher
by Zacks Equity Research
Medallion (MFIN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Near-Term Outlook Dim for SBIC & Commercial Finance Industry
by Swayta Shah
Lower interest rates, weak loan demand and coronavirus-related economic slowdown are likely to hurt the SBIC & commercial finance industry's near-term prospects.